Muhammad Waqas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Waqas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Hanzla Shahzad
Ameer‐ud‐Din Medical College Lahore Pakistan
3 shared publications - Muhammad Wajid Siddique
Ameer-ud-din Medical College Lahore, Pakistan
3 shared publications - Nazila Dalir
School of Medicine, St. George’s University, St. George’s, Grenada
2 shared publications - Filza Rahat
Department of Medicine, East Lancashire Hospitals NHS Trust, Blackburn, UK
1 shared publication - Mahnoor Shah
San Juan Regional Medical Center, Farmington, USA
1 shared publication - Mifrah Rahat Khan Sherwani
Division of Cardiology Duke University Hospital Durham North Carolina USA
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Urology Case Reports
- Vol. 69
Recognizing a duplicated inferior vena cava during radical nephrectomy for papillary renal cell carcinoma: A case report
- 23 October 2026
- Published by Elsevier in Urology Case Reports
- Vol. 69
Open AccessRecognizing a duplicated inferior vena cava during radical nephrectomy for papillary renal cell carcinoma: A case report
- Open Access
- 15 October 2026
- Published by Springer Nature in BMC Urology
Beyond conventional metastatic patterns: a case report of isolated omental metastasis from high-risk prostate adenocarcinoma
Background: Peritoneal and omental metastasis from prostate adenocarcinoma is rare and usually occurs in the setting of widespread disease. Isolated peritoneal involvement without skeletal or nodal disease is uncommon, and the mechanism of spread is not well understood. Case presentation: A 64-year-old man presented with lower urinary tract symptoms and was diagnosed with high-risk prostate adenocarcinoma (Gleason 4 + 5=9, WHO Grade Group 5) after transurethral resection of the prostate (TURP); post-operative prostate-specific antigen (PSA) was 7.8 ng/mL, and the pre-operative work-up was not available. Staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) showed locally invasive disease extending into the seminal vesicles and bladder base, without nodal or distant metastasis. He was treated with hormonal therapy and external beam radiotherapy, achieving a PSA nadir of 0.35 ng/mL. Despite a subsequent rise in PSA, a surveillance PSMA PET/CT was negative for recurrence. PSA continued to rise progressively, reaching 59.17 ng/mL, with new lower urinary tract symptoms. Repeat PSMA PET/CT showed ascites and diffuse PSMA-avid omental caking with peritoneal fat stranding, without local recurrence, lymphadenopathy, or osseous metastasis. Image-guided tru-cut biopsy of the omentum confirmed metastatic carcinoma compatible with the known prostatic primary. He was started on docetaxel with continued luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, and prednisolone, and remains under oncological surveillance. Conclusion: Peritoneal and omental recurrence can occur after TURP-diagnosed prostate cancer without involvement of the usual sites of spread, and a TURP-related iatrogenic contribution cannot be excluded. A negative PSMA PET/CT does not exclude progression; in selected patients with a marked, sustained PSA rise and new symptoms, repeat imaging may be considered when it is likely to alter management, and histopathological confirmation is required when an atypical metastatic site is suspected.
- 15 October 2026
- Published by Springer Nature in BMC Urology
Open AccessBeyond conventional metastatic patterns: a case report of isolated omental metastasis from high-risk prostate adenocarcinoma
Background: Peritoneal and omental metastasis from prostate adenocarcinoma is rare and usually occurs in the setting of widespread disease. Isolated peritoneal involvement without skeletal or nodal disease is uncommon, and the mechanism of spread is not well understood. Case presentation: A 64-year-old man presented with lower urinary tract symptoms and was diagnosed with high-risk prostate adenocarcinoma (Gleason 4 + 5=9, WHO Grade Group 5) after transurethral resection of the prostate (TURP); post-operative prostate-specific antigen (PSA) was 7.8 ng/mL, and the pre-operative work-up was not available. Staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) showed locally invasive disease extending into the seminal vesicles and bladder base, without nodal or distant metastasis. He was treated with hormonal therapy and external beam radiotherapy, achieving a PSA nadir of 0.35 ng/mL. Despite a subsequent rise in PSA, a surveillance PSMA PET/CT was negative for recurrence. PSA continued to rise progressively, reaching 59.17 ng/mL, with new lower urinary tract symptoms. Repeat PSMA PET/CT showed ascites and diffuse PSMA-avid omental caking with peritoneal fat stranding, without local recurrence, lymphadenopathy, or osseous metastasis. Image-guided tru-cut biopsy of the omentum confirmed metastatic carcinoma compatible with the known prostatic primary. He was started on docetaxel with continued luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, and prednisolone, and remains under oncological surveillance. Conclusion: Peritoneal and omental recurrence can occur after TURP-diagnosed prostate cancer without involvement of the usual sites of spread, and a TURP-related iatrogenic contribution cannot be excluded. A negative PSMA PET/CT does not exclude progression; in selected patients with a marked, sustained PSA rise and new symptoms, repeat imaging may be considered when it is likely to alter management, and histopathological confirmation is required when an atypical metastatic site is suspected.
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5364-5367
A case report on silent clear cell renal cell carcinoma with intraluminal ureteric extension: a pattern beyond conventional AJCC staging
Introduction: Renal cell carcinoma (RCC) usually presents with the classic three signs: flank pain, blood in the urine, and a palpable mass in the abdomen. Presentation of case: We present a case of a 54-year-old woman who exhibited altered bowel habits. Cholecystectomy was scheduled after the identification of gallstones; however, a preoperative CT scan inadvertently disclosed RCC. The tumor affected the renal vein and extended into the ureter. The patient underwent a radical nephrectomy, during which the renal vessels were tied off with Vicryl sutures, and the ureter was cut up to the vesicoureteral junction. Clinical discussion: To our knowledge, this constitutes an uncommon incidental discovery of clear cell carcinoma in a patient lacking typical RCC symptoms, demonstrating intraluminal extension into the ureter. This pattern of dissemination is not delineated in the current literature, nor is it referenced by the existing AJCC staging system. Conclusion: This case may indicate the necessity for reevaluation or alteration of the AJCC guidelines to accommodate intraluminal ureteric extension in clear cell RCC.
- 14 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5364-5367
Open AccessA case report on silent clear cell renal cell carcinoma with intraluminal ureteric extension: a pattern beyond conventional AJCC staging
Introduction: Renal cell carcinoma (RCC) usually presents with the classic three signs: flank pain, blood in the urine, and a palpable mass in the abdomen. Presentation of case: We present a case of a 54-year-old woman who exhibited altered bowel habits. Cholecystectomy was scheduled after the identification of gallstones; however, a preoperative CT scan inadvertently disclosed RCC. The tumor affected the renal vein and extended into the ureter. The patient underwent a radical nephrectomy, during which the renal vessels were tied off with Vicryl sutures, and the ureter was cut up to the vesicoureteral junction. Clinical discussion: To our knowledge, this constitutes an uncommon incidental discovery of clear cell carcinoma in a patient lacking typical RCC symptoms, demonstrating intraluminal extension into the ureter. This pattern of dissemination is not delineated in the current literature, nor is it referenced by the existing AJCC staging system. Conclusion: This case may indicate the necessity for reevaluation or alteration of the AJCC guidelines to accommodate intraluminal ureteric extension in clear cell RCC.